Risk of Acute Kidney Injury from Contrast-Media Procedure Low
Patients with previous acute kidney injury at highest risk of repeat injury.
The risk of developing an acute kidney injury (AKI) following imaging that requires contrast media is low, according to a study published in the Journal of the American College of Radiology.
Researchers from the UTHealth School of Public Health in Houston, Texas, evaluated risk predictors of AKI after contrast-media procedures performed on 2,737,020 people between January 1, 2012, and November 30, 2014. The information was collected from comprehensive medical and pharmacy commercial claims data.
Related article: Blood Flow Changes Found in Children with Chronic Kidney Disease
The results showed that AKI after a contrast-media procedure occurred in 26% of patients who underwent two or more procedures within a month. This compares with 9% of non-AKI cases. The overall incidence of AKI after a contrast-media procedure was 0.85%. Ten percent of patients who developed AKI had a recent previous episode of AKI. When AKI had occurred within 180 days of contrast administration, the odds of subsequent kidney injury was 9.39.
The researchers concluded while the overall risk of developing AKI after a contrast-media procedure, patients who did experience AKI shortly before the procedure had a higher risk of developing AKI again.
Burnout in Radiology: Key Risk Factors and Promising Solutions
June 9th 2025Recognizing the daunting combination of increasing imaging volume and workforce shortages, these authors discuss key risk factors contributing to burnout and moral injury in radiology, and potential solutions to help preserve well-being among radiologists.
The Reading Room: Artificial Intelligence: What RSNA 2020 Offered, and What 2021 Could Bring
December 5th 2020Nina Kottler, M.D., chief medical officer of AI at Radiology Partners, discusses, during RSNA 2020, what new developments the annual meeting provided about these technologies, sessions to access, and what to expect in the coming year.
Mammography AI Platform for Five-Year Breast Cancer Risk Prediction Gets FDA De Novo Authorization
June 2nd 2025Through AI recognition of subtle patterns in breast tissue on screening mammograms, the Clairity Breast software reportedly provides validated risk scoring for predicting one’s five-year risk of breast cancer.
